Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02454088 · ClinicalTrials.gov registry record · NA
A Single-Center Investigator-Initiated Evaluator-Bilateral-Comparison Pilot Study of Injectable Calcium Hydroxylapatite With and Without Triamcinolone Acetate for the Treatment of Volume Loss to Dorsum Areas of the Hands
A NA study of Volume Loss to Dorsum of Hands, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02454088: Completed NA study of Volume Loss to Dorsum of Hands, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
NCT02454088 is a NA study of Volume Loss to Dorsum of Hands that has completed, run by Goldman, Butterwick, Fitzpatrick and Groff. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02454088, a NA study of Volume Loss to Dorsum of Hands, has completed, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This will be a single-center, investigator-initiated, double-blinded, randomized, bilateral-comparison pilot study of injectable Calcium hydroxylapatite with and without Triamcinolone acetate for the treatment of volume loss to the dorsum areas of the hands.
Primary Outcome
The primary analyses of efficacy will be based on the change from Baseline through Day 360 for assessment (based on the Merz Validated Hand Grading Score).
Conditions Studied
Interventions
- OTHER Calcium Hydroxylapatite and Triamcinolone acetate
- DEVICE Calcium Hydroxylapatite and Placebo
Study Locations (1)
California
- Cosmetic Laser Dermatology - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-11 |
| Phase | NA |
What the finished NCT02454088 record still lists
NCT02454088 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Volume Loss to Dorsum of Hands appearing as the primary indexed condition, and to 2 interventions - of which Calcium Hydroxylapatite and Triamcinolone acetate is the first listed.
NCT02454088 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02454088 about?
NCT02454088 is a clinical study titled "A Single-Center Investigator-Initiated Evaluator-Bilateral-Comparison Pilot Study of Injectable Calcium Hydroxylapatite With and Without Triamcinolone Acetate for the Treatment of Volume Loss to Dorsum Areas of the Hands". This will be a single-center, investigator-initiated, double-blinded, randomized, bilateral-comparison pilot study of injectable Calcium hydroxylapatite with and without Triamcinolone acetate for the treatment of volume loss to the dorsum areas of the hands.
What is the current status of trial NCT02454088?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2015-05. Estimated completion is 2016-11.
What conditions does trial NCT02454088 study?
This clinical trial studies the following conditions: Volume Loss to Dorsum of Hands.
What interventions are being tested in trial NCT02454088?
The interventions under investigation include: Calcium Hydroxylapatite and Triamcinolone acetate (OTHER), Calcium Hydroxylapatite and Placebo (DEVICE).
Who is sponsoring clinical trial NCT02454088?
This trial is sponsored by Goldman, Butterwick, Fitzpatrick and Groff, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02454088 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02454088's enrollment target sits among peer trials
20 1768th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia